Pharmaceutical

AAO 2024: Nanoscope Therapeutics’ MCO-010 RESTOREs vision in RP patients

This trial investigated the potential of Nanoscope Therapeutics' MCO-010 to restore vision in patients with retinitis pigmentosa (RP).

Oct 22, 2024 - 04:00
AAO 2024: Nanoscope Therapeutics’ MCO-010 RESTOREs vision in RP patients
This trial investigated the potential of Nanoscope Therapeutics' MCO-010 to restore vision in patients with retinitis pigmentosa (RP).
Read the original article

Tags:

Previous Article

Thermo Fisher’s Oncomine gains FDA approval as brain tumor diagnostic

Next Article

Sanofi’s $17bn sale of Opella to US investors advances following government deal

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Health care developers are impressed by Apple Vision Pro, but they aren’t diving head first

STAT+: Health care developers are impressed by Apple Vi...

Feb 7, 2024

Opinion: Compounding pharmacies offer a fix for shortages of essential drugs

Opinion: Compounding pharmacies offer a fix for shortag...

May 15, 2023

In pigs, researchers show ultrasound could be used for 3D printing inside the body

In pigs, researchers show ultrasound could be used for ...

Dec 7, 2023